No Data
No Data
Theriva Biologics Highlights Key Achievements in Q3 2024
Theriva Biologics Analyst Ratings
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Announces Target Price $6
Express News | Theriva Biologics Inc : Maxim Group Cuts Target Price to $6 From $25
Theriva Biologics | 10-Q: Q3 2024 Earnings Report
Theriva Biologics | 8-K: Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
baozhang : How do you see next Monday?